Pharma BD Deal Intelligence
Roche paid $175M for Piramed's PI3K platform; both derived oncology drugs (pictilisib, taselisib) failed in the clinic, and it took Roche/Genentech until 2024 — a third drug generation and 16 years later — to finally get a PI3K-alpha inhibitor (inavolisib) approved.
Full analysis, sources & comparables →Ranks computed across 828 graded deals (Critic + Outcome Score both present).
FierceBiotech describes Roche's $175M Piramed grab as part of a 2008 dealmaking spree consolidating PI3K inhibitor rights.
C&EN positions the deal as a strategic doubling-down on PI3K, complementing Genentech's existing oncology partnership with Piramed.
Source summaries from our enrichment pipeline; follow links for originals.
All 4 sources with sentiment breakdown →
$160M upfront + $15M milestone; PI3K-alpha oncology, PI3K-delta inflammation
Roche paid $175M for Piramed's PI3K platform; both derived oncology drugs (pictilisib, taselisib) failed in the clinic, and it took Roche/Genentech until 2024 — a third drug generation and 16 years later — to finally get a PI3K-alpha inhibitor (inavolisib) approved.
Assessment window: 15yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Roche Holding AG / Piramed Pharma (this deal) | 2008 | $175M | 29 |
| Roche Holding AG / Chugai Pharmaceutical Co. Ltd. | 2002 | $1.4B | 100 |
| Roche Holding AG / Ventana Medical Systems Inc. | 2008 | $3.4B | 88 |
| Roche Holding AG / Corange Ltd. (Boehringer Mannheim Group) | 1997 | $11.0B | 88 |
| Roche Holding AG / Ventana Medical Systems Inc. | 2007 | $3.4B | 88 |
| Roche Holding AG / Foundation Medicine, Inc. | 2015 | $1.1B | 87 |
| Roche Holding AG / Foundation Medicine, Inc. | 2018 | $5.3B | 85 |
← Browse all deals · How we score deals
More: 2008 deals · Roche Holding AG deals